Formation of Genome Canada

1
BioSpain Barcelona November 30th, 2004 Fira de
Barcelona, Palacio de Congresos de Barcelona
2
Genomics / Proteomics
Molecular Biology
Bioinformatics
Automation
3
Organizational attributes correlate to an
organizations positioning along the discovery
and commercialization value chain
Mission
Scientific Promotion
Economic Development
Financial Gain
- Commercial Project Focus - Top-down Project
Selection - Micro Management
- Research Project Focus - Bottom-up Project
Selection - Macro Management
Organizational Attributes
Tech Transfer
Pure Research
Company Founding
Applied Research
Company Growth
Idea
Value Chain
RIKEN, Whitehead Institute, Sanger Institute
VIB Flanders, SSF Research, SCGTI
Genopole, Georgia Research Alliance
Primary Focus
NIH/SBIR
Secondary Focus
VCs
Capability
Source L.E.K. interviews and analysis
4
Creation of Genome Centres (2000-2001)
Genome Canada
5
National Competitions (2001-2004)
GA
Genome Canada
6
Genome Canada 386 million Partner Funding
469 million Total Funding 855 million
7
Agreements with Institutions (2001-2002)
Genome Canada
Eligible Participants
University
Industry
Government
8
Co-Funding (2001 2004)
Genome Canada
9
Summary of Funding Sources for Genome Canada
Approved Projects (November 2004)
Genome Canada 45 (386M)
Institutional 4 (31M)
Provincial 22 (190M)
Federal 8 (68M)
Foreign 9 (77M)
Industry/Private 12 (103M)
Note Categorisation of 62M in co-funding from
the most recent competition In applied health is
estimated.
10
Integration and Coordination
Genome Canada
11
Multi-Centre Research Activities
Genome Canada
12
International Context
13
Structural Genomics Consortium
14
Haplotype Map
15
Bovine Sequencing Consortium
16
Genome Canada / Swedish SSF
17
Genome CanadaGenoma España
GBC Grapevine GA Halibut Sole OGI
Neurological Disorders
18
(No Transcript)
19
Summary ofGenoma Espagña / Genome Canada
Projects
Nov 2004
20
Pleurogene Flatfish Genomics
21
Grapevine Genomics
22
Neurodevelopmental Diseases
23
Genome Canada Organization
24
(No Transcript)
25
150 rue Metcalfe Street, Suite 2100Ottawa,
OntarioCANADA K2P 1P1Tel [phone]Fax
[phone] info_at_genomecanada.ca www.genomecan
ada.ca
26
Patents in Genomics by Leading Countries(1991-200
2)
0 500 1,000 1,500 2,000 2,500
25,000
24,692
2,294
1,226
1,203
1,014
1,010
466
354
263
112
Compiled by Science-Metrix from USPTO data
27
Commercialization Strategies
28
Intellectual Property Integrators
Valley of Death
Discovery Research
Venture Capital

• I.P. Integrators
• Patenting
• Proof of Concept
• Complementary Technology
• Business Plan

Genome Canada
BDC
29
Future Connectivity
30
Intellectual Property Integrators
To capture and optimize the exploitation of
economic benefits from gt1 B in public investment
in genomics and proteomics. ACTIVITIES/TOOLS

• I.P. Awareness and Training for Scientists
• Patent Protection Services(Due
  Diligence/Disclosure/Provisional)
• Patent Extension Experiments
• Proof of Concept Experiments
• Development of Patent Strategy (one stop
  shopping)
• Data Mining and Complementary Patent
  Identification(Academia, Biotech and Pharma)
• Acquisition of Complementary Technology
• Develop Business Plan (Market Studies)
• Lead and Secure Seed/Pre-Seed Investment
• Identify Management Talent to Drive Opportunity

Services
Financing
31
Speed Wins
Phase I
Competition I
Competition II
Phase II
2009
2008
2007
2006
2005
2004
Competition III
Strategic Initiatives
32
What do we need from Genome Canada? 2005 - 20010

• Stability longer-term funding from our lead
  investor
• Diversity health, forestry, fisheries,
  agriculture, environment, ethics
• Applicability include applied competitions by
  sector
• Adaptability regional strategic activities IP
  agreements commercialization, etc.
• Credibility national support for genomics and
  proteomics

33
Public Outreach and Education